tiprankstipranks
Trending News
More News >
Fonar (FONR)
:FONR
Advertisement

Fonar (FONR) AI Stock Analysis

Compare
96 Followers

Top Page

FONR

Fonar

(NASDAQ:FONR)

Select Model
Select Model
Select Model
Neutral 64 (OpenAI - 4o)
Rating:64Neutral
Price Target:
$16.50
▲(8.34% Upside)
Fonar's overall stock score reflects strong financial performance in terms of revenue growth and gross profitability, but is tempered by concerns over declining net profit margins and cash flow issues. The technical analysis indicates weak momentum, and while the valuation is reasonable, the lack of a dividend yield may deter some investors. The absence of earnings call and corporate events data limits the assessment to these factors.

Fonar (FONR) vs. SPDR S&P 500 ETF (SPY)

Fonar Business Overview & Revenue Model

Company DescriptionFonar Corporation (FONR) is a medical technology company focused on the development and manufacturing of advanced magnetic resonance imaging (MRI) systems. The company operates primarily in the healthcare sector, providing innovative imaging solutions that enhance diagnostic capabilities for medical professionals. Fonar's core products include its patented upright MRI systems, which allow patients to be scanned in weight-bearing positions, resulting in improved diagnostic accuracy and patient comfort.
How the Company Makes MoneyFonar generates revenue primarily through the sale of its MRI systems and related equipment to hospitals, diagnostic centers, and medical facilities. The company also earns income from service and maintenance agreements for their MRI machines, providing ongoing support and upgrades to clients. Additionally, Fonar has established partnerships with healthcare providers and research institutions that may contribute to revenue through collaborative projects or shared clinical studies. The company's ability to capitalize on its niche market of upright MRI technology, coupled with ongoing service contracts, significantly contributes to its overall earnings.

Fonar Financial Statement Overview

Summary
Fonar demonstrates strong revenue growth and gross profitability, with a stable balance sheet characterized by low leverage. However, the decline in net profit margin and significant drop in free cash flow growth are areas of concern. The missing EBIT margin and ROE data for 2025 limit the full assessment of profitability and return on equity.
Income Statement
75
Positive
Fonar has shown consistent revenue growth over the years, with a notable increase in gross profit margin from 43.87% in 2024 to 81.67% in 2025. However, the net profit margin decreased from 17.66% in 2022 to 16.18% in 2025, indicating some pressure on profitability. The EBIT margin was not reported for 2025, which could be a concern. Overall, the company demonstrates strong revenue growth and gross profitability, but there are areas for improvement in net profitability.
Balance Sheet
70
Positive
The company maintains a healthy debt-to-equity ratio, which has decreased over time, indicating effective leverage management. However, the return on equity (ROE) was not reported for 2025, which limits the assessment of profitability relative to shareholder equity. The equity ratio remains stable, suggesting a solid capital structure. Overall, the balance sheet shows stability with low leverage, but missing ROE data is a limitation.
Cash Flow
60
Neutral
Fonar's cash flow statement reveals a significant decline in free cash flow growth, dropping by 99.98% in 2025, which is concerning. The operating cash flow to net income ratio is low, indicating potential challenges in converting income into cash. The free cash flow to net income ratio is stable at 1.0, suggesting that the company is generating sufficient cash relative to its net income. Overall, while the cash flow generation relative to income is adequate, the sharp decline in free cash flow growth is a significant risk.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue104.35M104.35M102.88M98.65M97.59M89.93M
Gross Profit42.90M85.22M45.14M45.75M47.01M43.47M
EBITDA18.24M16.30M28.25M24.61M31.65M23.45M
Net Income8.33M8.33M10.57M9.38M12.44M10.21M
Balance Sheet
Total Assets216.91M216.91M214.25M200.58M199.34M189.51M
Cash, Cash Equivalents and Short-Term Investments56.45M56.45M56.48M51.31M48.76M44.49M
Total Debt38.92M38.92M41.68M37.01M38.22M34.69M
Total Liabilities56.80M56.80M57.46M49.75M53.11M54.14M
Stockholders Equity172.61M172.61M165.97M157.91M150.29M138.42M
Cash Flow
Free Cash Flow7.47M7.47M13.27M10.13M10.67M14.27M
Operating Cash Flow11.26M2.02M14.09M14.47M15.30M19.09M
Investing Cash Flow-3.80M-3.80M-850.74K-4.34M-5.18M-4.82M
Financing Cash Flow-7.47M-7.47M-8.18M-7.57M-5.86M-6.61M

Fonar Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price15.23
Price Trends
50DMA
15.52
Negative
100DMA
15.39
Positive
200DMA
14.71
Positive
Market Momentum
MACD
-0.02
Positive
RSI
47.80
Neutral
STOCH
35.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FONR, the sentiment is Neutral. The current price of 15.23 is below the 20-day moving average (MA) of 15.64, below the 50-day MA of 15.52, and above the 200-day MA of 14.71, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 47.80 is Neutral, neither overbought nor oversold. The STOCH value of 35.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FONR.

Fonar Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
$268.40M20.4210.79%17.11%45.34%
64
Neutral
$97.55M12.604.92%1.43%-20.12%
57
Neutral
$112.14M-22.44-9.80%15.16%-39.18%
52
Neutral
$497.58M-3.70-25.57%-1.36%-479.49%
52
Neutral
$522.89M-1.67%-0.85%61.31%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
44
Neutral
$260.79M-32.87%17.36%9.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FONR
Fonar
15.46
0.07
0.45%
XTNT
Xtant Medical Holdings
0.80
0.26
48.15%
VREX
Varex Imaging
11.99
-1.16
-8.82%
VMD
Viemed Healthcare
6.92
-2.17
-23.87%
NNOX
Nano-X Imaging
4.06
-1.95
-32.45%
CTKB
Cytek Biosciences
4.26
-0.63
-12.88%

Fonar Corporate Events

Fonar Corporation Delays Annual Report Filing
Sep 12, 2025

Fonar Corporation has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending June 30, 2025. The company cites unexpected delays as the primary reason for the late filing, which could not be avoided without unreasonable effort or expense. Fonar anticipates submitting the report within 15 calendar days following the original due date. The company does not expect any significant changes in its financial results from the previous fiscal year. Fonar is actively working to comply with all regulatory requirements, as confirmed by the signature of Timothy R. Damadian, President and CEO.

The most recent analyst rating on (FONR) stock is a Buy with a $17.50 price target. To see the full list of analyst forecasts on Fonar stock, see the FONR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 24, 2025